Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
Quality of life not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation (any cause) · adults with bronchiectasis
Macrolides showed no clear difference in hospitalisation: all cause compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
Quality of life ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis
1 finding from 1 review
Quality of life: change · adults with bronchiectasis
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides showed no clear difference in ≥ 1 exacerbation compared with no intervention (moderate certainty).
1 finding from 1 review
Hospitalisation ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful treatment of exacerbation: number of participants cured. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Successful treatment of exacerbation: number of participants with P aeruginosa eradication. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review